Twist Bioscience Corp (0ME.SG)
| Previous close | 25.50 |
| Open | 25.30 |
| Bid | 26.75 x 280000 |
| Ask | 27.06 x 190000 |
| Day's range | 25.30 - 26.49 |
| 52-week range | 20.44 - 57.82 |
| Volume | |
| Avg. volume | 29 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 03 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Twist Bioscience Begins Shipping Commercial Product from Synthetic DNA Manufacturing Factory of the Future
SOUTH SAN FRANCISCO, Calif., January 26, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the shipments of the first products from its second manufacturing site, the Factory of the Future, in Wilsonville, Oregon.
- Business Wire
Twist Bioscience to Report Fiscal 2023 First Quarter Financial Results on Friday, February 3, 2023
SOUTH SAN FRANCISCO, Calif., January 19, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2023 first quarter ended December 31, 2022, before the opening of the market on Friday, February 3, 2023. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. East
- Business Wire
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics
SOUTH SAN FRANCISCO, Calif. & CAMBRIDGE, Mass. & ROSTOCK, Germany & BERLIN, January 10, 2023--Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the launch of three next-generation sequencing (NGS) target enrichment panels to support rar
